Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
99% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. MYGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MYGN' s Cash to Debt Range Over the Past 10 Years
Min: 16.5  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.89
MYGN's Equity to Asset is ranked higher than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. MYGN: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
MYGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.71  Med: 0.90 Max: 0.96
Current: 0.89
0.71
0.96
F-Score: 8
Z-Score: 15.58
M-Score: -2.77
WACC vs ROIC
2.10%
20.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.09
MYGN's Operating margin (%) is ranked higher than
89% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. MYGN: 22.09 )
Ranked among companies with meaningful Operating margin (%) only.
MYGN' s Operating margin (%) Range Over the Past 10 Years
Min: -39.89  Med: 35.81 Max: 39.24
Current: 22.09
-39.89
39.24
Net-margin (%) 14.29
MYGN's Net-margin (%) is ranked higher than
85% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. MYGN: 14.29 )
Ranked among companies with meaningful Net-margin (%) only.
MYGN' s Net-margin (%) Range Over the Past 10 Years
Min: -33.42  Med: 22.63 Max: 42
Current: 14.29
-33.42
42
ROE (%) 15.20
MYGN's ROE (%) is ranked higher than
83% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. MYGN: 15.20 )
Ranked among companies with meaningful ROE (%) only.
MYGN' s ROE (%) Range Over the Past 10 Years
Min: -19.82  Med: 18.28 Max: 30.71
Current: 15.2
-19.82
30.71
ROA (%) 13.29
MYGN's ROA (%) is ranked higher than
93% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. MYGN: 13.29 )
Ranked among companies with meaningful ROA (%) only.
MYGN' s ROA (%) Range Over the Past 10 Years
Min: -17.54  Med: 16.98 Max: 28.73
Current: 13.29
-17.54
28.73
ROC (Joel Greenblatt) (%) 112.04
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. MYGN: 112.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -238.09  Med: 251.31 Max: 362.64
Current: 112.04
-238.09
362.64
Revenue Growth (3Y)(%) 19.20
MYGN's Revenue Growth (3Y)(%) is ranked higher than
86% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.10 vs. MYGN: 19.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.6  Med: 20.10 Max: 45.7
Current: 19.2
1.6
45.7
EBITDA Growth (3Y)(%) -0.80
MYGN's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. MYGN: -0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 12.15 Max: 53
Current: -0.8
-10.2
53
EPS Growth (3Y)(%) -6.00
MYGN's EPS Growth (3Y)(%) is ranked lower than
55% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. MYGN: -6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.9  Med: 4.15 Max: 67.9
Current: -6
-16.9
67.9
» MYGN's 10-Y Financials

Financials (Next Earnings Date: 2016-08-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MYGN Guru Trades in Q2 2015

Jim Simons 639,800 sh (+133.76%)
Ken Fisher 88,050 sh (unchged)
Mario Gabelli 25,000 sh (unchged)
Chase Coleman Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
First Pacific Advisors 233,200 sh (-7.13%)
Chuck Royce 2,823,203 sh (-17.07%)
» More
Q3 2015

MYGN Guru Trades in Q3 2015

Paul Tudor Jones 11,274 sh (New)
Jim Simons 856,600 sh (+33.89%)
Ken Fisher 89,775 sh (+1.96%)
Mario Gabelli 25,000 sh (unchged)
First Pacific Advisors Sold Out
Chuck Royce 2,271,668 sh (-19.54%)
» More
Q4 2015

MYGN Guru Trades in Q4 2015

RS Investment Management 1,998,910 sh (New)
Joel Greenblatt 196,364 sh (New)
Paul Tudor Jones 21,386 sh (+89.69%)
Jim Simons 949,600 sh (+10.86%)
Mario Gabelli 25,000 sh (unchged)
Ken Fisher 89,775 sh (unchged)
Chuck Royce 1,414,898 sh (-37.72%)
» More
Q1 2016

MYGN Guru Trades in Q1 2016

RS Investment Management 2,178,740 sh (+9.00%)
Jim Simons 1,034,800 sh (+8.97%)
Paul Tudor Jones 22,391 sh (+4.70%)
Joel Greenblatt 201,527 sh (+2.63%)
Ken Fisher 89,783 sh (+0.01%)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,284,698 sh (-9.20%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:INCR, NAS:CPHD, NAS:NEOG, NAS:PRAH, OTCPK:CZMWY, OTCPK:DSRLF, NAS:KANG, NAS:EXAS, OTCPK:SWTUY, NAS:AFFX, NAS:PRXL, NAS:AXDX, NAS:ABAX, NAS:ALOG, NAS:GHDX, NAS:VIVO, NAS:FMI, NAS:NEO, NAS:NTRA, NAS:QDEL » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Company's business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.

Guru Investment Theses on Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics - Oct 08, 2014

Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. It was the Fund’s largest holding at the end of June.

From Chuck Royce (Trades, Portfolio)’s Royce Premier Fund Second Quarter 2014 Manager Commentary.

Check out Chuck Royce latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 20.93
MYGN's P/E(ttm) is ranked higher than
73% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.11 vs. MYGN: 20.93 )
Ranked among companies with meaningful P/E(ttm) only.
MYGN' s P/E(ttm) Range Over the Past 10 Years
Min: 9.06  Med: 19.72 Max: 63.15
Current: 20.93
9.06
63.15
Forward P/E 17.18
MYGN's Forward P/E is ranked higher than
78% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. MYGN: 17.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.93
MYGN's PE(NRI) is ranked higher than
73% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.79 vs. MYGN: 20.93 )
Ranked among companies with meaningful PE(NRI) only.
MYGN' s PE(NRI) Range Over the Past 10 Years
Min: 9.06  Med: 18.79 Max: 40.65
Current: 20.93
9.06
40.65
Price/Owner Earnings (ttm) 22.66
MYGN's Price/Owner Earnings (ttm) is ranked higher than
68% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.58 vs. MYGN: 22.66 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.68  Med: 22.79 Max: 113.28
Current: 22.66
9.68
113.28
P/B 2.83
MYGN's P/B is ranked higher than
57% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. MYGN: 2.83 )
Ranked among companies with meaningful P/B only.
MYGN' s P/B Range Over the Past 10 Years
Min: 2.32  Med: 3.74 Max: 8.23
Current: 2.83
2.32
8.23
P/S 3.00
MYGN's P/S is ranked higher than
52% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. MYGN: 3.00 )
Ranked among companies with meaningful P/S only.
MYGN' s P/S Range Over the Past 10 Years
Min: 2.32  Med: 4.91 Max: 14.31
Current: 3
2.32
14.31
PFCF 14.60
MYGN's PFCF is ranked higher than
83% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.85 vs. MYGN: 14.60 )
Ranked among companies with meaningful PFCF only.
MYGN' s PFCF Range Over the Past 10 Years
Min: 7.62  Med: 17.00 Max: 142.72
Current: 14.6
7.62
142.72
POCF 14.16
MYGN's POCF is ranked higher than
65% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.37 vs. MYGN: 14.16 )
Ranked among companies with meaningful POCF only.
MYGN' s POCF Range Over the Past 10 Years
Min: 7.22  Med: 16.00 Max: 43.64
Current: 14.16
7.22
43.64
EV-to-EBIT 11.75
MYGN's EV-to-EBIT is ranked higher than
71% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. MYGN: 11.75 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 9.80 Max: 44
Current: 11.75
-102.5
44
EV-to-EBITDA 10.12
MYGN's EV-to-EBITDA is ranked higher than
66% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.01 vs. MYGN: 10.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.40 Max: 38.5
Current: 10.12
-161.3
38.5
PEG 1.61
MYGN's PEG is ranked higher than
74% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. MYGN: 1.61 )
Ranked among companies with meaningful PEG only.
MYGN' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 0.90 Max: 3.38
Current: 1.61
0.47
3.38
Shiller P/E 26.62
MYGN's Shiller P/E is ranked higher than
70% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 43.43 vs. MYGN: 26.62 )
Ranked among companies with meaningful Shiller P/E only.
MYGN' s Shiller P/E Range Over the Past 10 Years
Min: 25.86  Med: 51.91 Max: 2553
Current: 26.62
25.86
2553
Current Ratio 5.63
MYGN's Current Ratio is ranked higher than
78% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. MYGN: 5.63 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 2.2  Med: 5.96 Max: 20.28
Current: 5.63
2.2
20.28
Quick Ratio 5.25
MYGN's Quick Ratio is ranked higher than
81% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. MYGN: 5.25 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.2  Med: 5.96 Max: 20.28
Current: 5.25
2.2
20.28
Days Inventory 67.12
MYGN's Days Inventory is ranked higher than
58% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. MYGN: 67.12 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.31 Max: 60.67
Current: 67.12
22.14
60.67
Days Sales Outstanding 43.91
MYGN's Days Sales Outstanding is ranked higher than
77% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. MYGN: 43.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 72.25
Current: 43.91
38.41
72.25
Days Payable 32.35
MYGN's Days Payable is ranked lower than
68% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. MYGN: 32.35 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 52.25  Med: 86.08 Max: 280.85
Current: 32.35
52.25
280.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.33
MYGN's Price/Net Cash is ranked lower than
73% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.51 vs. MYGN: 18.33 )
Ranked among companies with meaningful Price/Net Cash only.
MYGN' s Price/Net Cash Range Over the Past 10 Years
Min: 3.23  Med: 9.01 Max: 101.14
Current: 18.33
3.23
101.14
Price/Net Current Asset Value 7.94
MYGN's Price/Net Current Asset Value is ranked lower than
59% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.06 vs. MYGN: 7.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.41  Med: 6.40 Max: 27.64
Current: 7.94
2.41
27.64
Price/Tangible Book 5.33
MYGN's Price/Tangible Book is ranked lower than
57% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. MYGN: 5.33 )
Ranked among companies with meaningful Price/Tangible Book only.
MYGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.53  Med: 3.83 Max: 19.86
Current: 5.33
1.53
19.86
Price/Projected FCF 0.82
MYGN's Price/Projected FCF is ranked higher than
90% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. MYGN: 0.82 )
Ranked among companies with meaningful Price/Projected FCF only.
MYGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.64  Med: 1.27 Max: 20.87
Current: 0.82
0.64
20.87
Price/Median PS Value 0.61
MYGN's Price/Median PS Value is ranked higher than
77% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. MYGN: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
MYGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.47  Med: 1.42 Max: 9.19
Current: 0.61
0.47
9.19
Price/Peter Lynch Fair Value 2.69
MYGN's Price/Peter Lynch Fair Value is ranked lower than
54% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. MYGN: 2.69 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.47  Med: 1.08 Max: 3.25
Current: 2.69
0.47
3.25
Price/Graham Number 2.23
MYGN's Price/Graham Number is ranked higher than
68% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. MYGN: 2.23 )
Ranked among companies with meaningful Price/Graham Number only.
MYGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.01  Med: 1.95 Max: 3.35
Current: 2.23
1.01
3.35
Earnings Yield (Greenblatt) (%) 8.47
MYGN's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. MYGN: 8.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 8.80 Max: 22.7
Current: 8.47
2.3
22.7
Forward Rate of Return (Yacktman) (%) 13.39
MYGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.32 vs. MYGN: 13.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -19.9  Med: 3.70 Max: 29.4
Current: 13.39
-19.9
29.4

More Statistics

Revenue (TTM) (Mil) $757.2
EPS (TTM) $ 1.48
Beta0.07
Short Percentage of Float42.85%
52-Week Range $28.82 - 46.24
Shares Outstanding (Mil)70.30

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 761 797 872 1,075
EPS ($) 1.59 1.86 2.15 2.75
EPS w/o NRI ($) 1.59 1.86 2.15 2.75
EPS Growth Rate
(3Y to 5Y Estimate)
14.94%
Dividends Per Share ($)
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
Myriad Genetics downgraded by BofA/Merrill Jul 29 2016
Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9 Jul 26 2016
Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9 Jul 26 2016
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : July 26,... Jul 26 2016
Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of... Jul 11 2016
Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of... Jul 11 2016
Myriad Genetics myChoice Cancer Test Findings Encourage Jul 01 2016
Myriad Genetics: Study Data Drives Growth, Competition Rife Jul 01 2016
MYRIAD GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 30 2016
MYRIAD GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 29 2016
Myriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's... Jun 29 2016
Myriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in... Jun 29 2016
Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League... Jun 10 2016
MYRIAD GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 07 2016
Myriad Gets $200 Million More For Share Repurchase Program Jun 07 2016
Myraid Genetics increases share buyback program by $200 million Jun 07 2016
Myriad Board Approves $200 Million Increase in Share Repurchase Program Jun 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)